. Author manuscript; available in PMC: 2021 Aug 12.

Published in final edited form as: Cancer Discov. 2020 Aug 14;10(12):1842–1853. doi: 10.1158/2159-8290.CD-20-0047

Table 1.

Association between two different ctDNA dynamics measurements and survival in three cohorts of patients with solid tumors receiving immune checkpoint blockade

Study	Study 1108 (n = 69)		ATLANTIC (n = 66)		Study 10 (n = 36)
Treatment	Durvalumab		Durvalumab		Durvalumab + tremelimumab

PFS
	n (%)	HR (95% CI)	n (%)	HR (95% CI)	n (%)	HR (95% CI)
On-treatment VAF = 0	9 (13)	0.55 (0.25-1.24)	9 (14)	0.72 (0.31-1.69)	11 (31)	0.12 (0.04-0.37)
Ratio < 50%	27 (39)	0.28 (0.14-0.57)	24 (36)	0.3 (0.15-0.60)	15 (42)	0.11 (0.04-0.30)

OS
	n (%)	HR (95% CI)	n (%)	HR (95% CI)	n (%)	HR (95% CI)
On-treatment VAF = 0	9 (13)	0.31 (0.1-1.02)	9 (14)	0 (0-∞)^a	11 (31)	0.05 (0.01-0.39)
Ratio < 50%	27 (39)	0.29 (0.16-0.53)	24 (36)	0.29 (0.10-0.84)	15 (42)	0.12 (0.04-0.37)

All patients with on-treatment VAF = 0 were censored.